A clinical trial to learn about the effects of DAK539 on the blood levels of repaglinide, midazolam, drospirenone, and ethinyl estradiol in people with advanced cancer
Фаза 1 – тестване на безопасността при малка група хора
Заболявания:
Patients with advanced malignancies
Спонсор: Novartis Pharma AG
Налично на:
БГ
Обобщение
Trial status: Authorised
Кой може да участва
Age group: 65+ years, 18-64 years
Gender: Female, Male
Target enrollment: 24 participants
БГ
EN